US20140080977A1 - Hydrophilized antimicrobial polymers - Google Patents

Hydrophilized antimicrobial polymers Download PDF

Info

Publication number
US20140080977A1
US20140080977A1 US14/087,188 US201314087188A US2014080977A1 US 20140080977 A1 US20140080977 A1 US 20140080977A1 US 201314087188 A US201314087188 A US 201314087188A US 2014080977 A1 US2014080977 A1 US 2014080977A1
Authority
US
United States
Prior art keywords
composition
comonomer
bactericidal
antimicrobial
copolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/087,188
Inventor
Jeffrey P. Youngblood
Philippe H. Sellenet
Thomas R. Stratton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/509,915 external-priority patent/US20070048249A1/en
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Priority to US14/087,188 priority Critical patent/US20140080977A1/en
Assigned to PURDUE RESEARCH FOUNDATION reassignment PURDUE RESEARCH FOUNDATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SELLENET, PHILIPPE H., STRATTON, THOMAS R., YOUNGBLOOD, JEFFREY P.
Publication of US20140080977A1 publication Critical patent/US20140080977A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F26/00Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F26/06Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a heterocyclic ring containing nitrogen
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18Testing for antimicrobial activity of a material
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/06Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a heterocyclic ring containing nitrogen

Definitions

  • bactericidal properties can be strongly influenced by whether the polycation or a composition containing the polycation is soluble. In some instances the bactericidal property is most apparent in an insoluble form, which is not particularly amenable to killing microorganisms. In other instances the bactericidal activity is lost when the polycation is cross-linked or otherwise rendered insoluble.
  • Application of bactericidal polymers may also be limited by their use in brushes, their insolubility in solution, or by their unfavorable biocompatibility characteristics.
  • bactericidal formulations possessing having improved bactericidal, hydrophilicity/wettability and biocompatibility characteristics suitable for rendering materials or areas bactericidal and for killing airborne and/or waterborne microorganisms.
  • the present invention is directed to polymeric compositions providing improved bactericidal or antimicrobial, hydrophilicity/wettability, and biocompatibility characteristics.
  • the present invention provides a bactericidal or antimicrobial composition, including a hydrophilic first cornonomer polymerized to a second cornonomer to form a polymeric composition, where the polymeric composition is more soluble and/or more bactericidal or antimicrobial in an aqueous solution than either of the first comonorner or the second comonorner alone.
  • the present invention provides a quaternized bactericidal or antimicrobial composition, in which poly(4-vinylpyridine) (PVP) is copolymerized with hydroxyethylmethacrylate (HEMA) or poly(ethyleneglycol) methacrylate (PEGMA).
  • PVP poly(4-vinylpyridine)
  • HEMA hydroxyethylmethacrylate
  • PEGMA poly(ethyleneglycol) methacrylate
  • the present invention provides an aqueous composition
  • a polymeric composition formed from a hydrophilic first comonomer polymerized to a second comonomer and water
  • the second comonomer comprises polycationic species, polycationic derivatives or combinations therefrom.
  • the composition further comprises a netural thickener or cationic thickener.
  • the polymeric composition is more hydrophilic than either of the first comonomer or the second comonomer alone and/or where the polymeric composition is more bactericidal or antimicrobial than either of the first cornonomer or the second comonomer alone.
  • the hydrophilic first comonomer comprises hydroxyethylmethacrylate or poly(ethyleneglycol) methacrylate; the second comonomer plurality of quaternary ammonium groups, more preferably quaternized poly(4-vinylpyridine); and the thickener is selected from the group consisting of natural gums, pectins, alginates, gelatins, carageenans, flours, starches, dextrins, casein, cellulose derivatives, polyvinyl pyrrolidones, polyaminoalkyl methacrylates, and polyaminoalkyl acrylates, preferably a cellulose derivative, more preferably hydroxyethyl cellulose.
  • the present invention provides a method for rendering a material or area bactericidal or antimicrobial in which a bactericidal or antimicrobial composition of the present invention is applied to a medium or device in an amount suitable for killing or significantly reducing the number of bacteria or microorganisms in or on the treated medium or device compared to an untreated medium or device.
  • the present invention provides a method for killing or significantly reducing the number of bacteria or microorganisms on a material or area treated with a bactericidal or antimicrobial composition of the present invention.
  • the present invention provides a method for identifying a polymer having suitable bactericidal or antimicrobial activity in which a hydrophilic first comonomer is polymerized to a second comonomer to form a bactericidal or antimicrobial polymeric composition, where the polymeric composition is determined to have suitable bactericidal or antimicrobial activity if the polymeric composition has a higher bactericidalor antimicrobial activity in an aqueous solution than either of the hydrophilic first cornonomer or second comonomer alone (or treated similarly as the polymeric composition).
  • the present invention provides an article comprising a polymeric composition posited on a surface of a medium.
  • the polymeric composition is formed from a hydrophilic first comonomer polymerized to a second comonorner.
  • the hydrophilic first comonomer comprises a methacrylate comonomer.
  • the second comonomer comprises quaternized poly(4-vinylpyridine).
  • the medium is selected from the group consisting of catheters, needles, sutures, stents, implantable medical devices, contact lenses, root canal fillers, wound dressings, burn dressings, tissue culture plates, fibers and paper.
  • the hydrophilic first cornonomer is poly(ethyleneglycol) methacrylate or hydroxyethylmethacrylate and the medium is fibers or paper.
  • compositions include their use in catheters, stents, fibers, paper and other implantable medical devices, contact lenses, root canal fillers, wound dressings, and the like.
  • FIG. 1 is a schematic showing (A) the radical polymerization of P(VP-co-HEMA) and (B) quaternization of P(VP-co-HEMA)-HB.
  • FIG. 2 is graph of bactericidal results for surface testing of P(VP-co-HEMA)-HB.
  • FIG. 3 is a graph of advancing and receding contact angles for P(VP-co-HEMA).
  • FIG. 4 is a graph of bactericidal results for testing of P(VP-co-PEGMA1100).
  • FIG. 5 is a graph of dead epithelial cells as a function of PPEGMA, P(VP-co-PEGMA) or control polymer.
  • the term “monomer” refers to a relatively simple compound, usually containing carbon and of low molecular weight, which can react to form a polymer by combining with itself or with other monomers.
  • polymer and “polymeric composition” are used interchangeably to denote a product of a polymerization reaction, and are inclusive of homopolymers, copolymers, terpolymers, etc.
  • polymerization and “polymerization reaction” are inclusive of homopolymerizations, copolymerizations, terpolymerizations, and the like, and include all types of copolymerizations such as random, graft, block, and the like.
  • the polymers in the bactericidal or antimicrobial composition on may be prepared in accordance with any suitable polymerization process, including slurry polymerization, solution polymerization, emulsion polymeriza ion, gas phase polymerization, and high pressure polymerization processes.
  • nonomer refers to a monomer, copolymer, or polymer which can copolymerize with itself or with at least one different monomer, copolymer, or polymer in a copolymer reaction, the result of which can be a polymer, copolymer or polymeric composition.
  • copolymer refers to a polymer which can copolymerize with itself or with at least one different comonorner, polymer, or copolymer in a polymerization reaction or it can refer to a product resulting from a polymerization reaction of two comonomers.
  • the copolymer may be identified or named in terms of the monomer(s) from which the copolymer is produced.
  • corresponding comonomer “corresponding copolymer,” and “corresponding polymer” are used to relate comonomers, copolymers, or polymers, respectively, sharing a common set of monomeric units between e.g., distinct polymeric compositions.
  • the common comonomers, copolymers, or polymer need not be identical in terms of the molecular weight(s) or molar ratio(s) of commonly shared monomeric units.
  • corresponding molecular weight is used to relate molecular weight(s) of corresponding comonomers, copolymers, or polymers, respectively, in distinct polymeric compositions in which the common comonomers, copolymers, or polymers differ from one another by molecular weight(s) or commonly shared monomeric units within the corresponding comonomer, copolymer or polymer.
  • corresponding molar ratio is used to relate molar ratio(s) of corresponding comonomers, copolymers, or polymers, respectively, in distinct polymeric compositions in which the common comonomers, copolymers, or polymers differ from one another by molar ratio(s) or commonly shared monomeric units within the corresponding comonorner, copolymer or polymer.
  • bactericidal is used to interchangeably denote any one of the following: (i) a comonomer, polymer, copolymer, polymeric composition suitably formulated to kill, reduce the growth, number, viability and/or metabolic activity of one or more bacteria; (ii) a material, substance, medium, device, or area treated with a bactericidal comonomer, polymer, copolymer, polymeric composition so as to kill, reduce the growth, number, viability and/or metabolic activity of one or more bacteria.
  • antimicrobial is used interchangeably denote any one of the following: (i) a comonomer, polymer, copolymer, polymeric composition suitably formulated to kill, reduce the growth, number, viability and/or metabolic activity of one or more bacteria, fungi, protozoans, or viruses; (ii) a material, substance, medium, device, or area treated with an antimicrobial comonomer, polymer, copolymer, polymeric composition so as to kill, reduce the growth, number, viability and/or metabolic activity of one or more bacteria, fungi, protozoans, or viruses.
  • microorganism and “microbe” are used interchangeably to denote microscopic living organisms including for example, bacteria, fungi, protozoans, and viruses.
  • aqueous solution refers to a solution in which water is the solvent.
  • a treatable medium refers to a treatable material, treatable substance, treatable device, or treatable area in which “treatable” refers to a capacity to be rendered bactericidal or antimicrobial by a bactericidal or antimicrobial cornonomer, polymer, or copolymer.
  • a treatable medium may have a defined physical form, but may include liquid (e.g., water, aqueous solution) or gaseous materials (e.g., air) also.
  • the phrases “significantly reducing the growth of bacteria” and “significantly reducing bacterial growth” are used interchangeably to denote one or more of the following conditions, including (i) a condition in which the metabolic activity of at least 50% of the microorganisms of a particular type exposed to a treated medium is terminated or reduced compared to bacteria of that particular type exposed to an untreated medium over a fixed period of time; (ii) a condition where there is 50% or less of one or more bacterial types present in and/or on a treated medium compared to the number of bacteria exposed to an untreated medium; and/or (iii) a condition resulting when one or more types of bacteria adhere 50% less to a treated medium compared to an untreated medium.
  • the degree of bacterial growth reduction with respective to conditions (i)-(iii) may range from 50% to greater 99.9%.
  • significantly bactericidal denotes a comonomer, polymer, copolymer, composition, polymeric composition, material, substance or treated area in which the bactericidal comonomer, polymer, copolymer, composition, polymeric composition, material, substance or treated area is suitably formulated to significantly reduce the growth, number, viability and/or metabolic activity of bacteria by at least 50%.
  • biocompatible refers to a material that is substantially non-toxic in the in vivo environment of its intended use, and that is not substantially rejected by the patient's physiological system (i.e., is non-antigenic). This can be gauged by the ability of a material to pass the biocompatibility tests set forth in International Standards Organization (ISO) Standard No. 10993 and/or the U.S. Pharmacopeia (USP) 23 and/or the U.S. Food and Drug Administration (FDA) blue book memorandum No.
  • ISO International Standards Organization
  • USP U.S. Pharmacopeia
  • FDA U.S. Food and Drug Administration
  • G95-1 entitled “Use of International Standard IS0-10993, Biological Evaluation of Medical Devices Part-1: Evaluation and Testing.” Typically, these tests measure a material's toxicity, infectivity, pyrogenicity, irritation potential, reactivity, hemolytic activity, carcinogenicity and/or immunogenicity.
  • a biocompatible structure or material when introduced into a majority of patients, will not cause a significantly adverse, long-lived or escalating biological reaction or response, and is distinguished from a mild, transient inflammation which typically accompanies surgery or implantation of foreign objects into a living organism.
  • a bactericidal or antimicrobial polymeric composition of the present invention includes a hydrophilic first comonomer polymerized to a second comonorner, where the polymeric composition is more soluble and/or more bactericidal or antimicrobial in an aqueous solution than either of the first comonorner or the second comonorner alone.
  • the polymeric composition of the present invention were found to have unexpected hydophilizing and/or wettability properties providing enhanced bactericidal or antimicrobial activity compared to either comonomer alone.
  • the second comonomer may be inherently bactericidal or antimicrobial or it may be rendered bactericidal or antimicrobial after a subsequent step (e.g., polymerization) and/or chemical modification (e.g., quaternization) of alkyl groups.
  • a subsequent step e.g., polymerization
  • chemical modification e.g., quaternization
  • the polymeric composition is further modified by chemical modification, such as quaternization
  • the polymeric composition is more hydrophilic and/or bactericidal or antimicrobial than a similarly modified (by e.g., quaternization) second comonomer alone.
  • Bactericidal or antimicrobial comonomers or those capable of being rendered bactericidal or antimicrobial are copolymerized to a hydrophilizing cornonomer.
  • Exemplary second comonomers for polymerization to a hydrophilizing comonorner may include a variety of vinyl monomers capable of free radical polymerization and/or quaternization. Accordingly, these comonomers may include, but are not limited to, vinyl amines, such as N,N-dimethylvinylarnine; allyl amines; vinyl esters, such as vinyl acetate; alkyl acrylates; and vinyl chloride.
  • a pyridinium-type comonomer such as vinyl pyridine or 4-vinylpyridine, is quaternized after polymerization to a hydrophilizing comonomer.
  • the second comonorner composition may include or be chemically linked to a suitable bactericidal or antimicrobial moiety, including, but not limited to polycationic species, polycationic derivatives or combinations therefrom.
  • Polycationic species may contain two or more quaternary ammonium groups with a molecular weight ranging from several hundred Daltons to a few hundred thousand Daltons.
  • the quaternary ammonium groups may be part of a ring or they may be acyclic. Examples include but are not limited to: polyionenes, poly(diallyldimethylammonium chloride), dimethylamine-epichlorohydrin copolymers and irnidazole-epichlorohydrin copolymers.
  • Suitable bactericidal or antimicrobial comonomers for use in the present invention may include the quaternary ammonium group-containing polymers disclosed in U.S. Pat. No. 4,482,680, which are incorporated by reference herein.
  • Polycationic species may contain two or more amine groups.
  • the amine groups can be primary, secondary, tertiary, or mixtures thereof.
  • the amine groups may be part. of a ring or they may be acyclic. Examples include but are not limited to: polyethyleneimines, polypropyleneimines, polyvinylamines, polyallylamines, polydiallylamines, polyamidoamines, polyaminoalkylmethacrylates, polylysines, and mixtures thereof.
  • the polycationic species may also be a modified polyamine with at least one amine group substituted with at least one other functional group. Examples include ethoxylated and alkoxylated polyamines and alkylated polyamines. Other suitable bactericidal or antimicrobial comonomers or those that may be rendered bactericidal or antimicrobial may be identified and/or used in accordance with the applications and objectives set forth in the specification and claims.
  • Quaternization may be carried out using alkylating agents, including but not limited to alkyl halides (such as hexyl bromide), alkyl sulfonates, alkyl mesylates, alkyl tosylates, or other alkylating agents possessing a suitable leaving group. Quaternization reduces self-polymerization of the bactericidal or antimicrobial comonorner upon polymerization with the hydrophilizing comonorner. Quaternization may confer increased bactericidal or antimicrobial activity and is typically carried out after polymerization, since quaternized polymers are unpolymerizable.
  • alkylating agents including but not limited to alkyl halides (such as hexyl bromide), alkyl sulfonates, alkyl mesylates, alkyl tosylates, or other alkylating agents possessing a suitable leaving group. Quaternization reduces self-polymerization of the
  • Quaternized alkyl groups and/or other cationic chains may be attracted to and/or promote interaction and penetration negatively charged bacterial cell walls on account of their lipophilic nature.
  • Alkyl chain lengths of quaternizing agents and overall hydrophilicilipophilic balance may affect bactericidal or antimicrobial activity of the polymeric compositions of the present invention. Accordingly, these variables may be modified to optimize or improve bactericidal or antimicrobial activity of the polymeric compositions.
  • Hydrophilizing comonomers of the present invention confer increased wettability or hydrophilicity to one or more surfaces of the polymeric composition in aqueous solutions, including water.
  • the polymeric composition is more wettable than a bactericidal or antimicrobial comonomer or a comonorner rendered bactericidal or antimicrobial by quaternization, such as poly(4-vinylpyridine).
  • Suitable hydrophilizing monomers or copolymers may include, but are not limited to, ethylene glycol (ethylyene oxide); polyethylene glycol derivatives, including poly(ethyleneglycol) methacrylate (PEGMA), poly(ethyleneglycol) acrylate, and vinyl polyethylene glycol; vinyl acetate; poly(vinyl alcohol); vinyl pyrrolidone and poly(vinyl pyrrolidone); vinyl pyrrolidinone and poly(vinyl pyrrolininone); vinyl oxazoline and poly(vinyl oxazoline); vinyl foramide and poly(vinyl foramide); hydroxyalkyl acrylates and hydroxyaikyl methacrylates, such as hydroxyethyl methacrylate (HEMA) and hydroxyethyl acrylate; methacrylamide; acrylamide and methacrylamide based monomers, such as acrylamide, N,N-dimethyl acrylamide, N-ethyl acrylamide, N-iso
  • Hydrophilic polymeric compositions and methods for hydrophilizing polymeric materials, including the use of high energy treatments, are disclosed in U.S. Pat. Appl. No. 20050008839, the contents of which are expressly incorporated by reference in their entirety, also may be used.
  • the hydrophilizing comonorner is biocompatible.
  • Standard assays may be utilized to evaluate biocompatibility, including but not limited to viabilitylcytotoxicity mammalian cell assays and the like.
  • Representative hydrophilizing comonomers or copolymers include hydroxyethylmethacrylate (HEMA) and poly(ethyleneglycol) methacrylate (PEGMA).
  • HEMA is widely used in biomedical applications and devices, most prominently soft contact lenses. HEMA, with 37.8% water per weight, is typical of hydrogels. Preferably, the molar ratio of HEMA cornonomer in the polymeric composition is equal to or greater than about 90 to 1.
  • PEGMA is a biocompatible polymer which possesses several important properties, such as good solubility in both organic and aqueous media, low toxicity, immunogenicity and nonbiodegradability.
  • the molar molecular weight of PEGMA comonomer in the bactericidal or antimicrobial composition is equal to or greater than 300, more preferably between about 300 and about 2000, including but not limited to 1100.
  • the molar ratio of PEGMA comonomer in the polymeric composition is equal to or less than about 10 to 1; equal to or less than about 25 to 1; equal to or greater than about 75 to 1; equal to or greater than about 95 to 1; equal to or greater than about 99 to 1.
  • Hydrophilicity or wettability can be evaluated by any suitable methodology known in the art, including contact angle testing and tensionometry testing.
  • Contact angle testing of polymeric compositions may be carried out by dip coating microscope slides in solutions with copolymer dissolved in chloroform and methanol and obtaining contact angle measurements using e.g., a Ramé-Hart Advanced Goniometer.
  • Contact angles may be characterized as advancing or receding, the difference being whether or not the angle is taken when moving onto a dry surface or moving off a wet surface. Advancing angles may be used for surface energy determinations, receding angles for characterizing other surface characteristics.
  • Polymeric bactericidal or antimicrobial compositions may be rendered hydrophilic by engineering them to have advancing contact angles with water of less than or equal to about 90 degrees, preferably less than or equal to about 45 degrees, more preferably less than or equal to about 30 degrees, less than or equal to 15 degrees after 30 seconds of spreading.
  • the disclosed bactericidal or antimicrobial compositions are suitably formulated to significantly reduce the growth, number, viability and/or metabolic activity of bacteria or microorganisms.
  • a bactericidal or antimicrobial composition may be formulated to significantly reduce bacterial or antimicrobial growth from a treated medium by a factor of at least 50%.
  • a bactericidal or antimicrobial composition may be formulated to significantly reduce bacterial or microbial growth from a treated medium by at least 60%, by at least 70%, by at least 80%, by at least 90%, by at least 95%, by at least 99%, or by at least 99.9%.
  • the bactericidal or antimicrobial composition may be applied as a coating to at least one portion or surface of a medium or medical device, such as a catheter, or an implantable medical device, such as a stent.
  • a medium or medical device such as a catheter, or an implantable medical device, such as a stent.
  • Various methods may be used to apply the comonomers or bactericidal or antimicrobial polymers as a coating to the surface of the medical device. Suitable methods for applying coatings may include, but are not limited to the methods disclosed in U.S. Pat. No. 5,509,899 and U.S. Pat. No. 6,221,425, the contents of which are expressly incorporated by reference in their entirety.
  • Comonomers may be applied to a surface and subsequently polymerized.
  • the bactericidal or antimicrobial polymer composition may be applied directly to the surface of the medical device.
  • one or more comonomers or bactericidal polymers may be combined with water and sprayed onto the medical device.
  • the medical device may be dipped into a solution containing the bactericidal or antimicrobial polymer.
  • the comonomer or bactericidal or antimicrobial polymer may be present in the solution in an amount from about 50% to about 98% by weight, particularly from about 70% to about 90% by weight, and applied to the surface of the medical device.
  • the viscosity of the monomeric or polymeric solution can be adjusted depending upon the particular application and circumstances. In general, when dipping the medical device into the solution, higher viscosities will cause more of the bactericidal or antimicrobial polymer to remain on the surface of the device. Thus, if thicker coatings are desired, the viscosity can be increased. The viscosity of the solution can be increased by minimizing the amount of water in the solution. Additionally, thickeners, such as a polyacrylamide, can be added to the solution. The viscosity of the solution may also be increased by partially polymerizing the monomer.
  • the present invention provides an antimicrobial or antibacterial composition
  • an antibacterial polymeric composition comprising an antibacterial polymeric composition and water.
  • Other solvents may be added to the composition including alcohols such as ethanol, for example, if desired, but the addition of an alcohol is not necessary for the antimicrobial or antibacterial properties of the composition.
  • the antimicrobial or antibacterial composition is preferably in liquid form and may be applied to the skin of a human or mammal. Because the copolymer of the present invention will not evaporate and remains present for some time after application, the antimicrobial or antibacterial composition provides long-lasting antimicrobial effects. Compositions which make which make use of quickly evaporating ethanol for the antimicrobial properties do not provide long-lasting antimicrobial effects and can also dry out the skin.
  • a thickener or gelling agent may be added to the composition.
  • Any thickener or gelling agent which is compatible with the antibacterial or antimicrobial polymeric composition may be used.
  • the thickener is suitable for human or mammal use, more preferably the thickener is approved by the Food and Drug Administration (FDA).
  • FDA Food and Drug Administration
  • the formation of an electrolyte between the antibacterial or antimicrobial polymeric composition and the thickener diminishes efficacy. Because the antibacterial or antimicrobial polymeric composition comprises a polycation chain, it is desirable to use a neutral or cationic thickener.
  • cationic thickeners include for example, aminoalkyl methacrylates, alkylaminoalkyl methacrylates, dialkylaminoalkyl methacrylates, aminoalkyl acrylates, alkylaminoalkyl acrylates, dialkylaminoalkyl acrylates.
  • the cationic thickener is an aminoalkyl methacrylate, more preferably aminoethyl methacrylate.
  • neutral thickeners include natural gums, including for example carrageenans, acacia, guar, guargum, hydroxypropyl guar, karaya gum, kelp, locust beangurn, tragacanth gum, xanthan gum, alginates and the like; pectins; gelatins; flours and starches including for example, oat flour, potato starch, wheat flour, wheat starch, and the like; agars; dextrins; and casein; cellulose derivatives, including for example, carboxymethyl hydroxyethyl cellulose, cellulose, hydroxybutyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose,hydroxypropyl methyl cellulose, methyl cellulose, microcrystalline cellulose, and the like; and poly(vinyl pyrrolidone).
  • the thickener is a cellulose derivative, more preferably hydroxyethyl cellulose.
  • the amount of thickener present in the composition depends upon the desired viscosity of the composition. To achieve the desired viscosity, the thickener may be present in the composition in an amount from about 1.3% wt. % to about 25 wt. % of the total composition, dependent on the viscosifying agent or agents chosen.
  • the antimicrobial or antibacterial composition may be used by itself or as an additive to another product.
  • the composition When used by itself, the composition is applied to the skin, preferably the hands, in an amount from about 1 to about 10 mL, preferably about 2 to about 5 mL.
  • the composition is rubbed over the skin to distribute the composition for absorption onto the skin.
  • the present invention provides articles comprising an antibacterial or antimicrobial polymeric composition of the present invention posited on a surface of a medium.
  • the medium may be any article in which it is desirable to render a surface or part of a surface antibacterial or antimicrobial, including for example, catheters, needles, sutures, stents, implantable medical devices, contact lenses, root canal fillers, wound dressings, bum dressings, tissue culture plates, fibers and paper.
  • the antibacterial or antimicrobial polymeric composition may be posited on a surface by applying the polymeric composition which comprises water and optionally another solvent and allowing the water or other solvent to evaporate.
  • a sheet of paper may be coated by forming a polymeric composition in water and optionally another solvent which does not dissolve paper, applying the polymeric composition to the entire surface of the paper and allowing the water or other solvent to dry, thereby forming a polymer coating over the entire surface of the paper.
  • the hydrophilic first comonomer and second comonorner may be grafted to the surface of a medium by plasma grafting and then quaternized with an alkyl bromide to form the antimicrobial surface.
  • an alkyl bromide for example, 4-vinyl pyridine and poly(ethylene glycol) methyl ether methacrylate may be grafted to the surface of paper via plasma grafting and then quarternized with bromohexane to form the antimicrobial surface.
  • the surface or more specifically paper surface may be acylated by reacting it with 4-bromobutyrylchloride while immersed in an appropriate solvent.
  • the polymeric composition formed for example, from 4-vinyl-pyridine and poly(ethylene glycol) methyl ether methacrylate may then be quaternized by the surface alkyl bromide groups.
  • the antibacterial or antimicrobial polymeric composition may be incorporated into a natural or synthetic fiber.
  • the polymeric composition may be incorporated on or into fibers used for clothing or paper. Paper made from such fiber may be suitable as a food wrapping, part of a temporary wound dressing, as a disinfectant wipe, or for paper used in medical settings such as doctors' offices and hospitals including magazines.
  • the polymeric composition may be soluble or insoluble, depending on whether the desired product should be able to release the antibacterial or antimicrobial polymeric composition or retain the antibacterial or antimicrobial polymeric composition.
  • the polymeric composition may be temporarily posited on the fibers for release onto a desired surface or into a desired environment at a later time.
  • a soluble polymeric composition may be used in a disinfectant wipe.
  • the disinfectant wipe which may be an alcohol based disinfectant wipe, releases the antibacterial or antimicrobial polymeric composition to another surface, imparting long-lasting antimicrobial properties to the applied surface.
  • the present invention provides methods for rendering a material or area bactericidal or antimicrobial. In a further example, the present invention provides a method for killing or significantly reducing the number of bacteria or microorganisms on a material or area treated with a bactericidal or antimicrobial composition of the present invention.
  • a bactericidal or antimicrobial composition of the present invention is applied to a medium or medical device in an amount sufficient to kill or significantly reducing the number of bacteria or microbes in or on the treated medium compared to an untreated medium.
  • a bactericidal or antimicrobial composition according to the present invention is applied to a medium or medical device in an amount sufficient to kill at least one bacterium or microbe or significantly reduce bacterial or microbial growth compared to an untreated medium.
  • the bacteria may be Gram-positive or Gram-negative.
  • the bactericidal or antimicrobial composition may be is included in or coated onto a catheter, stent, implantable medical device, contact lens, root canal filler, or wound dressing.
  • the treated medium may include natural or synthetic materials, implantable devices, or bodily surfaces.
  • the treated medium may be contact with an aqueous environment, such as water or the inside of a patient or other vertebrate organism.
  • the treated medium may be contact with air or air and/or air borne bacteria in an external environment or an enclosed bodily organ, such as lung.
  • Biocompatibility may be evaluated by any suitable methodology known in the art, including one or more viability/cytotoxicity assays known to those of ordinary skill in the art.
  • the present invention provides a method for identifying a polymer having suitable bactericidal or antimicrobial activity.
  • a hydrophilizing first comonomer may be polymerized to a second comonomer and a bactericidal or antimicrobial polymeric composition is formed.
  • the bactericidal or antimicrobial polymeric composition may be applied to a medium to form a first treated medium and the medium may be separately treated with the second comonomer used in the first treated medium.
  • the first treated medium and the second treated medium may be separately contacted with a plurality of bacteria or microbes. Whether the first treated medium is more bactericidal or antimicrobial than the second treated medium may be determined.
  • a first polymeric composition and a second polymeric composition differing by molecular weight with regard to one or more corresponding comonomers may be separately applied to a medium and tested to identify a polymeric composition having improved bactericidal or antimicrobial activity.
  • a first polymeric composition and a second polymeric composition differing by molar ratio of their corresponding comonomers may be varied and may be separately applied to a medium and tested to identify a polymeric composition having improved bactericidal or antimicrobial activity.
  • a given polymeric composition may be rendered bactericidal or antimicrobial by quaternization after polymerizing the hydrophilizing first comonomer to the second comonomer. Accordingly, the quaternized polymeric composition would be deemed suitable for use in a bactericidal or antimicrobial composition if a medium containing or treated with the quaternized polymeric composition is more hydrophilic and/or bactericidal or antimicrobial than the same medium containing or treated with the quaternized second comonomer alone.
  • Bactericidal or antimicrobial activity may be evaluated using any suitable testing methodology used in the art, including, but not limited to, luminescence, optical density, or microscopic evaluation of bacterial or microbial growth or viability of coated and/or stained microscopic slides, plates or cultures.
  • Copolymers possessing suitable bactericidal properties and a suitable hydrophilicityibiocompatibility profile were obtained using a quaternized polymeric composition synthesized from 4-vinylpyridine and a biocompatible, hydrophilic comonomer, such as hydroxyethylmethacrylate (HEMA) or poly(ethyleneglycol) methacrylate.
  • HEMA hydroxyethylmethacrylate
  • poly(ethyleneglycol) methacrylate such as poly(ethyleneglycol) methacrylate.
  • Copolymers were synthesized by radical copolymerization with AIBN as initiator. The reactants were stirred at 70° C. for 48 hours under flowing N 2 to prevent oxidation. As the monomer contents were varied, the AIBN proportion was held constant to a massic ratio VP+PEGMA:AIBN equal to 22:1. To investigate the effects of hydrophilization, seven different compositions of VP with PEGMA300, PEGMA1100 and HEMA were synthesized, containing a molar percentage of VP of 10, 25, 50, 75, 90, 95 and 99.
  • Copolymers were quaternized with a 3-fold excess of hexyl bromide (HB) in a mixture of chloroform and methanol by reflux for 48 hr. They were precipitated in hexane, recovered and dried under vacuum.
  • HB hexyl bromide
  • VP, HEMA and PEGMA were purchased from Sigma Aldrich Co. (Milwaukee, USA). To avoid polymerization through heat or light, these monomers were inhibited with hydroquinone (HQ), 4-Methoxyphenol (MEHQ), and 2,6-di-tert-butyl-4-methylphenol (BHT) respectively.
  • HQ hydroquinone
  • MEHQ 4-Methoxyphenol
  • BHT 2,6-di-tert-butyl-4-methylphenol
  • the HQ and MEHQ inhibitors were removed by means of trap to trap while BHT was purified from PEGMA by column chromatography on silica gel (70-270 mesh) stationary phase.
  • An antimicrobial polymeric composition is prepared by dissolving the polymeric composition in water or a mixture of ethanol and water, such as 70% ethanol 30% water. The thickener is then added, and the resulting mixture is heated with stirring and kept below 70° C. until dissolution.
  • a P(VP-co-PEGMA300) hand gel was prepared by mixing 0.01 g of P(VP-co-HEMA) with 10 mL of water. Hydroxyethyl cellulose (0.013 a) was added, and the resulting mixture heated to 70° C., then cooled to room temperature.
  • Bactericidal tests were performed with a small quantity of the bacteria Escherichia coil O157:H7 in which the lux gene was added for luminescence, which provides a measure of metabolic growth or activity.
  • a sample was taken from a culture and placed in contact with the coated slides, by means of a pipette.
  • the intensity of the bioluminescence was recorded as a function of time for two hours with a photomultiplier tube. Reduced bioluminescence correlates with enhanced bactericidal activity.
  • P(VP-co-HEMA)-HB 95/5 and P(VP-co-HEMA)-HB 90/10 exhibited enhanced bactericidal activity compared to PVP-HB alone
  • the luminescence recorded for P(VP-co-HEMA)-HB 99/1 is similar to, but slightly less than that observed for PVP-HB alone. Accordingly, this copolymer, having one molar percent HEMA, displays properties similar to PVP-HB alone. However, a slide coated with P(VP-co-HEMA)-HB 99/1 kills bacteria faster than one coated with PVP-HB.
  • hydrophilized bactericidal polymers of the present invention to unexpectedly possess enhanced biocompatility characteristics, enhanced stabilization of blood cells compared to saline and decreased absorption to proteins and lipids.
  • P(VP-co-HEMA)-HB 90/10 the wettability effect is particularly evident.
  • This polymer exhibits a more optimal bactericidal activity, reflected in the fact that all bacteria were killed in 30 minutes. This further illustrates that that a slide coated with P(VP-co-HEMA)-HB 90/10 copolymer is significantly more bactericidal than pure PVP-HB.
  • the bacterial growth behavior for copolymers with PEGMA1100 can be seen in FIG. 4 .
  • Comonomer ratios of 90/10, 25/75, and 10/90 exhibited enhanced bactericidal activity compared to PVP-HB alone.
  • Extremely high bactericidal activity was seen with ratios of 99/1, presumably due to the large fraction of VP and improved wettability from PEGMA1100.
  • Copolymers with ratios ranging from 95/5 to 50/50 displayed bacterial results similar to PVP-HB.
  • P(VP-co-PEGMA1100)-HB 25/75 and 10/90 displayed a surprisingly high antibacterial activity. Although counterintuitive, this fact can have several explanations.
  • the molecular weight of P(VP-co-PEGMA1100)-HB 10/90 is much higher than other copolymer formulations of this system. This could increase bactericidal activity, because the copolymer possesses more alkyl tails to traverse the bacterial membranes.
  • the enhanced water wettability of the polymer may enable the polymer to better dissolve in and/or surround the bacteria in an aqueous medium, so as to facilitate more efficient bacterial killing.
  • PPEGMA300 (graph not shown) alone does not kill bacteria and actually improves growth due to its biocompatibility and hydrophilicity.
  • the improved biocompatibility and hydrophilicity is carried over into the P(VP-co-PEGMA300) copolymers with ratios from 0/100 to 50/50 thereby improving bacterial growth.
  • ratios greater 50/50 bactericidal activity was observed.
  • the optimum balance between spreading and VP content was found to be 75/25, in which half the bacteria were killed in the first 15 minutes. Overall, the bactericidal behavior of the PEGMA300 based polymers were reduced compared to PEGMA1100 based polymers.
  • PEGMA1100 has a significantly larger PEG size than PEGMA300. A smaller fraction of PEGMA1100 is thus necessary to hydrophilize P(VP-co-PEGMA1100). However, even for some similarly hydrophilized polymers, the PEGMA1100 materials exhibit superior bactericidal activity, possibly due to the enhanced protein resistance imparted by longer PEG chains in the polymers.
  • the enhanced bactericidal activity exhibited by the HEMA and PEGMA copolymers appears to result from enhanced wettability in aqueous solutions, allowing the polymer to better surround and/or gain access to the bacteria, so as to enhance bacterial killing.
  • FIG. 5 shows that an exemplary bactericidal PEGMA 1100 copolymer is non-toxic to mammalian cells.
  • Corneal epithelial cells were seeded onto polystyrene culture plates in phosphobuffered saline solution (PBS; pH 7.2) at a density of 3,500 cells/cm 2 for 24 hrs at 37° C. The cells were co-incubated for 4 hrs. with quaternized P(VP-co-PEGMA 1100) copolymer or PPEGMA control polymer in PBS at a concentration of 2.5 mg/ml, along with a PBS negative control media.
  • PBS phosphobuffered saline solution
  • Live cells were distinguished from dead cells using a fluorescence-based LIVE/DEAD viability/cytotoxicity assay system (Molecular Probes, Invitrogen Detection Technologies).
  • the assay system includes two probes, calcein AM, a fluorogenic esterase substrate producing a green fluorescent product in live cells having intracellular esterase activity, and ethidium homodimer-1, a high-affinity, red fluorescent dye only able to pass through and stain the compromised membranes of dead cells.
  • FIG. 5 plots the fraction of dead epithelial cells as a function of added bactericidal polymer or polymer control. As shown in FIG. 5 , treatment of epithelial cells with the bactericidal P(VP-co-PEGMA) polymer did not exhibit a statistically significant level of epithelial cell killing over that of the PEGMA polymer or PBS negative controls.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Materials For Medical Uses (AREA)

Abstract

A bactericidal or antimicrobial polymeric composition includes a hydrophilic first comonomer copolymerized to a second comonomer to produce a polymeric composition that is more hydrophilic or more bactericidal or antimicrobial in an aqueous solution than either of the comonomers alone. Methods for identifying bactericidal or antimicrobial polymers, methods for rendering materials bactericidal or antimicrobial, and methods for using bactericidal or antimicrobial compositions to kill or reduce bacterial or microbial growth are also described. Applications for the inventive compositions include their use in catheters, stents, medical devices, contact lenses; root canal fillers; fibers; paper; and/or wound dressing.

Description

  • The present patent document is a continuation-in-part of application Ser. No. 11/509,915, filed Aug. 24, 2006, which claims the benefit of the filing date under 35 U.S.C, §119(e) of Provisional U.S. patent application Ser. No. 60/711,234, filed Aug. 24, 2005. All of the foregoing applications are hereby incorporated by reference.
  • BACKGROUND
  • There is an ever-growing demand for materials suitable for killing harmful microorganisms. Such materials could be used to coat surfaces of common objects touched by people to render them antiseptic so as to prevent transmission of bacterial infections or to facilitate the killing of microorganisms in solution.
  • Various polycations are known to have bactericidal properties. However, their bactericidal properties can be strongly influenced by whether the polycation or a composition containing the polycation is soluble. In some instances the bactericidal property is most apparent in an insoluble form, which is not particularly amenable to killing microorganisms. In other instances the bactericidal activity is lost when the polycation is cross-linked or otherwise rendered insoluble. Application of bactericidal polymers may also be limited by their use in brushes, their insolubility in solution, or by their unfavorable biocompatibility characteristics. Accordingly, there is a need for bactericidal formulations possessing having improved bactericidal, hydrophilicity/wettability and biocompatibility characteristics suitable for rendering materials or areas bactericidal and for killing airborne and/or waterborne microorganisms.
  • BRIEF SUMMARY
  • The present invention is directed to polymeric compositions providing improved bactericidal or antimicrobial, hydrophilicity/wettability, and biocompatibility characteristics. In particular, the present invention provides a bactericidal or antimicrobial composition, including a hydrophilic first cornonomer polymerized to a second cornonomer to form a polymeric composition, where the polymeric composition is more soluble and/or more bactericidal or antimicrobial in an aqueous solution than either of the first comonorner or the second comonorner alone.
  • In a particular example, the present invention provides a quaternized bactericidal or antimicrobial composition, in which poly(4-vinylpyridine) (PVP) is copolymerized with hydroxyethylmethacrylate (HEMA) or poly(ethyleneglycol) methacrylate (PEGMA).
  • In another example, the present invention provides an aqueous composition comprising a polymeric composition formed from a hydrophilic first comonomer polymerized to a second comonomer and water, The second comonomer comprises polycationic species, polycationic derivatives or combinations therefrom. In some aspects the composition further comprises a netural thickener or cationic thickener. In some aspects, the polymeric composition is more hydrophilic than either of the first comonomer or the second comonomer alone and/or where the polymeric composition is more bactericidal or antimicrobial than either of the first cornonomer or the second comonomer alone. Preferably the hydrophilic first comonomer comprises hydroxyethylmethacrylate or poly(ethyleneglycol) methacrylate; the second comonomer plurality of quaternary ammonium groups, more preferably quaternized poly(4-vinylpyridine); and the thickener is selected from the group consisting of natural gums, pectins, alginates, gelatins, carageenans, flours, starches, dextrins, casein, cellulose derivatives, polyvinyl pyrrolidones, polyaminoalkyl methacrylates, and polyaminoalkyl acrylates, preferably a cellulose derivative, more preferably hydroxyethyl cellulose.
  • In another example, the present invention provides a method for rendering a material or area bactericidal or antimicrobial in which a bactericidal or antimicrobial composition of the present invention is applied to a medium or device in an amount suitable for killing or significantly reducing the number of bacteria or microorganisms in or on the treated medium or device compared to an untreated medium or device.
  • in another example, the present invention provides a method for killing or significantly reducing the number of bacteria or microorganisms on a material or area treated with a bactericidal or antimicrobial composition of the present invention.
  • In a further example, the present invention provides a method for identifying a polymer having suitable bactericidal or antimicrobial activity in which a hydrophilic first comonomer is polymerized to a second comonomer to form a bactericidal or antimicrobial polymeric composition, where the polymeric composition is determined to have suitable bactericidal or antimicrobial activity if the polymeric composition has a higher bactericidalor antimicrobial activity in an aqueous solution than either of the hydrophilic first cornonomer or second comonomer alone (or treated similarly as the polymeric composition).
  • In yet another example, the present invention provides an article comprising a polymeric composition posited on a surface of a medium. The polymeric composition is formed from a hydrophilic first comonomer polymerized to a second comonorner. The hydrophilic first comonomer comprises a methacrylate comonomer. The second comonomer comprises quaternized poly(4-vinylpyridine). The medium is selected from the group consisting of catheters, needles, sutures, stents, implantable medical devices, contact lenses, root canal fillers, wound dressings, burn dressings, tissue culture plates, fibers and paper. Preferably the hydrophilic first cornonomer is poly(ethyleneglycol) methacrylate or hydroxyethylmethacrylate and the medium is fibers or paper.
  • Applications for the inventive compositions include their use in catheters, stents, fibers, paper and other implantable medical devices, contact lenses, root canal fillers, wound dressings, and the like.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a schematic showing (A) the radical polymerization of P(VP-co-HEMA) and (B) quaternization of P(VP-co-HEMA)-HB.
  • FIG. 2 is graph of bactericidal results for surface testing of P(VP-co-HEMA)-HB.
  • FIG. 3 is a graph of advancing and receding contact angles for P(VP-co-HEMA).
  • FIG. 4 is a graph of bactericidal results for testing of P(VP-co-PEGMA1100).
  • FIG. 5 is a graph of dead epithelial cells as a function of PPEGMA, P(VP-co-PEGMA) or control polymer.
  • DETAILED DESCRIPTION
  • In order to provide a more clear and consistent understanding of the specification and claims, the following definitions are provided. Unless defined otherwise, all technical and scientific terms have the same meaning as is commonly understood by one of skill in the art to which this invention belongs.
  • The term “monomer” refers to a relatively simple compound, usually containing carbon and of low molecular weight, which can react to form a polymer by combining with itself or with other monomers.
  • The terms “polymer” and “polymeric composition” are used interchangeably to denote a product of a polymerization reaction, and are inclusive of homopolymers, copolymers, terpolymers, etc.
  • The terms “polymerization” and “polymerization reaction” are inclusive of homopolymerizations, copolymerizations, terpolymerizations, and the like, and include all types of copolymerizations such as random, graft, block, and the like. In general, the polymers in the bactericidal or antimicrobial composition on may be prepared in accordance with any suitable polymerization process, including slurry polymerization, solution polymerization, emulsion polymeriza ion, gas phase polymerization, and high pressure polymerization processes.
  • The term “comonomer” refers to a monomer, copolymer, or polymer which can copolymerize with itself or with at least one different monomer, copolymer, or polymer in a copolymer reaction, the result of which can be a polymer, copolymer or polymeric composition.
  • The term “copolymer” refers to a polymer which can copolymerize with itself or with at least one different comonorner, polymer, or copolymer in a polymerization reaction or it can refer to a product resulting from a polymerization reaction of two comonomers. The copolymer may be identified or named in terms of the monomer(s) from which the copolymer is produced.
  • The terms “corresponding comonomer,” “corresponding copolymer,” and “corresponding polymer” are used to relate comonomers, copolymers, or polymers, respectively, sharing a common set of monomeric units between e.g., distinct polymeric compositions. The common comonomers, copolymers, or polymer need not be identical in terms of the molecular weight(s) or molar ratio(s) of commonly shared monomeric units.
  • The phrase “corresponding molecular weight” is used to relate molecular weight(s) of corresponding comonomers, copolymers, or polymers, respectively, in distinct polymeric compositions in which the common comonomers, copolymers, or polymers differ from one another by molecular weight(s) or commonly shared monomeric units within the corresponding comonomer, copolymer or polymer.
  • The phrase “corresponding molar ratio” is used to relate molar ratio(s) of corresponding comonomers, copolymers, or polymers, respectively, in distinct polymeric compositions in which the common comonomers, copolymers, or polymers differ from one another by molar ratio(s) or commonly shared monomeric units within the corresponding comonorner, copolymer or polymer.
  • The term “bactericidal” is used to interchangeably denote any one of the following: (i) a comonomer, polymer, copolymer, polymeric composition suitably formulated to kill, reduce the growth, number, viability and/or metabolic activity of one or more bacteria; (ii) a material, substance, medium, device, or area treated with a bactericidal comonomer, polymer, copolymer, polymeric composition so as to kill, reduce the growth, number, viability and/or metabolic activity of one or more bacteria.
  • The term “antimicrobial” is used interchangeably denote any one of the following: (i) a comonomer, polymer, copolymer, polymeric composition suitably formulated to kill, reduce the growth, number, viability and/or metabolic activity of one or more bacteria, fungi, protozoans, or viruses; (ii) a material, substance, medium, device, or area treated with an antimicrobial comonomer, polymer, copolymer, polymeric composition so as to kill, reduce the growth, number, viability and/or metabolic activity of one or more bacteria, fungi, protozoans, or viruses.
  • The terms “microorganism” and “microbe” are used interchangeably to denote microscopic living organisms including for example, bacteria, fungi, protozoans, and viruses.
  • The term “aqueous solution” refers to a solution in which water is the solvent.
  • The term “medium” refers to a treatable material, treatable substance, treatable device, or treatable area in which “treatable” refers to a capacity to be rendered bactericidal or antimicrobial by a bactericidal or antimicrobial cornonomer, polymer, or copolymer. A treatable medium may have a defined physical form, but may include liquid (e.g., water, aqueous solution) or gaseous materials (e.g., air) also.
  • The phrases “significantly reducing the growth of bacteria” and “significantly reducing bacterial growth” are used interchangeably to denote one or more of the following conditions, including (i) a condition in which the metabolic activity of at least 50% of the microorganisms of a particular type exposed to a treated medium is terminated or reduced compared to bacteria of that particular type exposed to an untreated medium over a fixed period of time; (ii) a condition where there is 50% or less of one or more bacterial types present in and/or on a treated medium compared to the number of bacteria exposed to an untreated medium; and/or (iii) a condition resulting when one or more types of bacteria adhere 50% less to a treated medium compared to an untreated medium. The degree of bacterial growth reduction with respective to conditions (i)-(iii) may range from 50% to greater 99.9%.
  • The phrase “significantly bactericidal” denotes a comonomer, polymer, copolymer, composition, polymeric composition, material, substance or treated area in which the bactericidal comonomer, polymer, copolymer, composition, polymeric composition, material, substance or treated area is suitably formulated to significantly reduce the growth, number, viability and/or metabolic activity of bacteria by at least 50%.
  • The term “biocompatible” refers to a material that is substantially non-toxic in the in vivo environment of its intended use, and that is not substantially rejected by the patient's physiological system (i.e., is non-antigenic). This can be gauged by the ability of a material to pass the biocompatibility tests set forth in International Standards Organization (ISO) Standard No. 10993 and/or the U.S. Pharmacopeia (USP) 23 and/or the U.S. Food and Drug Administration (FDA) blue book memorandum No. G95-1, entitled “Use of International Standard IS0-10993, Biological Evaluation of Medical Devices Part-1: Evaluation and Testing.” Typically, these tests measure a material's toxicity, infectivity, pyrogenicity, irritation potential, reactivity, hemolytic activity, carcinogenicity and/or immunogenicity. A biocompatible structure or material, when introduced into a majority of patients, will not cause a significantly adverse, long-lived or escalating biological reaction or response, and is distinguished from a mild, transient inflammation which typically accompanies surgery or implantation of foreign objects into a living organism.
  • A bactericidal or antimicrobial polymeric composition of the present invention includes a hydrophilic first comonomer polymerized to a second comonorner, where the polymeric composition is more soluble and/or more bactericidal or antimicrobial in an aqueous solution than either of the first comonorner or the second comonorner alone. The polymeric composition of the present invention were found to have unexpected hydophilizing and/or wettability properties providing enhanced bactericidal or antimicrobial activity compared to either comonomer alone.
  • The second comonomer may be inherently bactericidal or antimicrobial or it may be rendered bactericidal or antimicrobial after a subsequent step (e.g., polymerization) and/or chemical modification (e.g., quaternization) of alkyl groups. Where the polymeric composition is further modified by chemical modification, such as quaternization, preferably, the polymeric composition is more hydrophilic and/or bactericidal or antimicrobial than a similarly modified (by e.g., quaternization) second comonomer alone.
  • Bactericidal or antimicrobial comonomers or those capable of being rendered bactericidal or antimicrobial are copolymerized to a hydrophilizing cornonomer. Exemplary second comonomers for polymerization to a hydrophilizing comonorner may include a variety of vinyl monomers capable of free radical polymerization and/or quaternization. Accordingly, these comonomers may include, but are not limited to, vinyl amines, such as N,N-dimethylvinylarnine; allyl amines; vinyl esters, such as vinyl acetate; alkyl acrylates; and vinyl chloride. In a preferred embodiment, a pyridinium-type comonomer, such as vinyl pyridine or 4-vinylpyridine, is quaternized after polymerization to a hydrophilizing comonomer.
  • The second comonorner composition may include or be chemically linked to a suitable bactericidal or antimicrobial moiety, including, but not limited to polycationic species, polycationic derivatives or combinations therefrom. Polycationic species may contain two or more quaternary ammonium groups with a molecular weight ranging from several hundred Daltons to a few hundred thousand Daltons. The quaternary ammonium groups may be part of a ring or they may be acyclic. Examples include but are not limited to: polyionenes, poly(diallyldimethylammonium chloride), dimethylamine-epichlorohydrin copolymers and irnidazole-epichlorohydrin copolymers. Suitable bactericidal or antimicrobial comonomers for use in the present invention may include the quaternary ammonium group-containing polymers disclosed in U.S. Pat. No. 4,482,680, which are incorporated by reference herein.
  • Polycationic species may contain two or more amine groups. The amine groups can be primary, secondary, tertiary, or mixtures thereof. The amine groups may be part. of a ring or they may be acyclic. Examples include but are not limited to: polyethyleneimines, polypropyleneimines, polyvinylamines, polyallylamines, polydiallylamines, polyamidoamines, polyaminoalkylmethacrylates, polylysines, and mixtures thereof.
  • The polycationic species may also be a modified polyamine with at least one amine group substituted with at least one other functional group. Examples include ethoxylated and alkoxylated polyamines and alkylated polyamines. Other suitable bactericidal or antimicrobial comonomers or those that may be rendered bactericidal or antimicrobial may be identified and/or used in accordance with the applications and objectives set forth in the specification and claims.
  • Quaternization may be carried out using alkylating agents, including but not limited to alkyl halides (such as hexyl bromide), alkyl sulfonates, alkyl mesylates, alkyl tosylates, or other alkylating agents possessing a suitable leaving group. Quaternization reduces self-polymerization of the bactericidal or antimicrobial comonorner upon polymerization with the hydrophilizing comonorner. Quaternization may confer increased bactericidal or antimicrobial activity and is typically carried out after polymerization, since quaternized polymers are unpolymerizable.
  • Quaternized alkyl groups and/or other cationic chains may be attracted to and/or promote interaction and penetration negatively charged bacterial cell walls on account of their lipophilic nature. Alkyl chain lengths of quaternizing agents and overall hydrophilicilipophilic balance may affect bactericidal or antimicrobial activity of the polymeric compositions of the present invention. Accordingly, these variables may be modified to optimize or improve bactericidal or antimicrobial activity of the polymeric compositions.
  • Hydrophilizing comonomers of the present invention confer increased wettability or hydrophilicity to one or more surfaces of the polymeric composition in aqueous solutions, including water. Preferably, the polymeric composition is more wettable than a bactericidal or antimicrobial comonomer or a comonorner rendered bactericidal or antimicrobial by quaternization, such as poly(4-vinylpyridine). Suitable hydrophilizing monomers or copolymers, may include, but are not limited to, ethylene glycol (ethylyene oxide); polyethylene glycol derivatives, including poly(ethyleneglycol) methacrylate (PEGMA), poly(ethyleneglycol) acrylate, and vinyl polyethylene glycol; vinyl acetate; poly(vinyl alcohol); vinyl pyrrolidone and poly(vinyl pyrrolidone); vinyl pyrrolidinone and poly(vinyl pyrrolininone); vinyl oxazoline and poly(vinyl oxazoline); vinyl foramide and poly(vinyl foramide); hydroxyalkyl acrylates and hydroxyaikyl methacrylates, such as hydroxyethyl methacrylate (HEMA) and hydroxyethyl acrylate; methacrylamide; acrylamide and methacrylamide based monomers, such as acrylamide, N,N-dimethyl acrylamide, N-ethyl acrylamide, N-isopropyl acrylamide, and hydroxymethyl acrylamide; monomers containing one or more of the following functional groups: hydroxy, amino, ammonium, ether, carboxylate, amide, and sulfoamide groups; and combinations or copolymers thereof. polyvinyloxazolines
  • Hydrophilic polymeric compositions and methods for hydrophilizing polymeric materials, including the use of high energy treatments, are disclosed in U.S. Pat. Appl. No. 20050008839, the contents of which are expressly incorporated by reference in their entirety, also may be used.
  • Preferably, the hydrophilizing comonorner is biocompatible. Standard assays may be utilized to evaluate biocompatibility, including but not limited to viabilitylcytotoxicity mammalian cell assays and the like. Representative hydrophilizing comonomers or copolymers include hydroxyethylmethacrylate (HEMA) and poly(ethyleneglycol) methacrylate (PEGMA).
  • HEMA is widely used in biomedical applications and devices, most prominently soft contact lenses. HEMA, with 37.8% water per weight, is typical of hydrogels. Preferably, the molar ratio of HEMA cornonomer in the polymeric composition is equal to or greater than about 90 to 1.
  • PEGMA is a biocompatible polymer which possesses several important properties, such as good solubility in both organic and aqueous media, low toxicity, immunogenicity and nonbiodegradability.
  • Preferably, the molar molecular weight of PEGMA comonomer in the bactericidal or antimicrobial composition is equal to or greater than 300, more preferably between about 300 and about 2000, including but not limited to 1100. Preferably, the molar ratio of PEGMA comonomer in the polymeric composition is equal to or less than about 10 to 1; equal to or less than about 25 to 1; equal to or greater than about 75 to 1; equal to or greater than about 95 to 1; equal to or greater than about 99 to 1.
  • Hydrophilicity or wettability can be evaluated by any suitable methodology known in the art, including contact angle testing and tensionometry testing. Contact angle testing of polymeric compositions may be carried out by dip coating microscope slides in solutions with copolymer dissolved in chloroform and methanol and obtaining contact angle measurements using e.g., a Ramé-Hart Advanced Goniometer. Contact angles may be characterized as advancing or receding, the difference being whether or not the angle is taken when moving onto a dry surface or moving off a wet surface. Advancing angles may be used for surface energy determinations, receding angles for characterizing other surface characteristics.
  • Polymeric bactericidal or antimicrobial compositions may be rendered hydrophilic by engineering them to have advancing contact angles with water of less than or equal to about 90 degrees, preferably less than or equal to about 45 degrees, more preferably less than or equal to about 30 degrees, less than or equal to 15 degrees after 30 seconds of spreading.
  • The disclosed bactericidal or antimicrobial compositions are suitably formulated to significantly reduce the growth, number, viability and/or metabolic activity of bacteria or microorganisms. A bactericidal or antimicrobial composition may be formulated to significantly reduce bacterial or antimicrobial growth from a treated medium by a factor of at least 50%. Further, a bactericidal or antimicrobial composition may be formulated to significantly reduce bacterial or microbial growth from a treated medium by at least 60%, by at least 70%, by at least 80%, by at least 90%, by at least 95%, by at least 99%, or by at least 99.9%.
  • The bactericidal or antimicrobial composition may be applied as a coating to at least one portion or surface of a medium or medical device, such as a catheter, or an implantable medical device, such as a stent. Various methods may be used to apply the comonomers or bactericidal or antimicrobial polymers as a coating to the surface of the medical device. Suitable methods for applying coatings may include, but are not limited to the methods disclosed in U.S. Pat. No. 5,509,899 and U.S. Pat. No. 6,221,425, the contents of which are expressly incorporated by reference in their entirety.
  • Comonomers may be applied to a surface and subsequently polymerized. Alternatively, the bactericidal or antimicrobial polymer composition may be applied directly to the surface of the medical device. In particular, one or more comonomers or bactericidal polymers may be combined with water and sprayed onto the medical device. Alternatively, the medical device may be dipped into a solution containing the bactericidal or antimicrobial polymer. The comonomer or bactericidal or antimicrobial polymer may be present in the solution in an amount from about 50% to about 98% by weight, particularly from about 70% to about 90% by weight, and applied to the surface of the medical device.
  • The viscosity of the monomeric or polymeric solution can be adjusted depending upon the particular application and circumstances. In general, when dipping the medical device into the solution, higher viscosities will cause more of the bactericidal or antimicrobial polymer to remain on the surface of the device. Thus, if thicker coatings are desired, the viscosity can be increased. The viscosity of the solution can be increased by minimizing the amount of water in the solution. Additionally, thickeners, such as a polyacrylamide, can be added to the solution. The viscosity of the solution may also be increased by partially polymerizing the monomer.
  • In another example, the present invention provides an antimicrobial or antibacterial composition comprising an antibacterial polymeric composition and water. Other solvents may be added to the composition including alcohols such as ethanol, for example, if desired, but the addition of an alcohol is not necessary for the antimicrobial or antibacterial properties of the composition. The antimicrobial or antibacterial composition is preferably in liquid form and may be applied to the skin of a human or mammal. Because the copolymer of the present invention will not evaporate and remains present for some time after application, the antimicrobial or antibacterial composition provides long-lasting antimicrobial effects. Compositions which make which make use of quickly evaporating ethanol for the antimicrobial properties do not provide long-lasting antimicrobial effects and can also dry out the skin.
  • To ease application and improve aesthetics, a thickener or gelling agent may be added to the composition. Any thickener or gelling agent which is compatible with the antibacterial or antimicrobial polymeric composition may be used. Preferably the thickener is suitable for human or mammal use, more preferably the thickener is approved by the Food and Drug Administration (FDA). Without wishing to be bound by theory, the formation of an electrolyte between the antibacterial or antimicrobial polymeric composition and the thickener diminishes efficacy. Because the antibacterial or antimicrobial polymeric composition comprises a polycation chain, it is desirable to use a neutral or cationic thickener.
  • Examples of cationic thickeners include for example, aminoalkyl methacrylates, alkylaminoalkyl methacrylates, dialkylaminoalkyl methacrylates, aminoalkyl acrylates, alkylaminoalkyl acrylates, dialkylaminoalkyl acrylates. Preferably the cationic thickener is an aminoalkyl methacrylate, more preferably aminoethyl methacrylate.
  • Examples of neutral thickeners include natural gums, including for example carrageenans, acacia, guar, guargum, hydroxypropyl guar, karaya gum, kelp, locust beangurn, tragacanth gum, xanthan gum, alginates and the like; pectins; gelatins; flours and starches including for example, oat flour, potato starch, wheat flour, wheat starch, and the like; agars; dextrins; and casein; cellulose derivatives, including for example, carboxymethyl hydroxyethyl cellulose, cellulose, hydroxybutyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose,hydroxypropyl methyl cellulose, methyl cellulose, microcrystalline cellulose, and the like; and poly(vinyl pyrrolidone). Preferably, the thickener is a cellulose derivative, more preferably hydroxyethyl cellulose.
  • The amount of thickener present in the composition depends upon the desired viscosity of the composition. To achieve the desired viscosity, the thickener may be present in the composition in an amount from about 1.3% wt. % to about 25 wt. % of the total composition, dependent on the viscosifying agent or agents chosen.
  • The antimicrobial or antibacterial composition may be used by itself or as an additive to another product. When used by itself, the composition is applied to the skin, preferably the hands, in an amount from about 1 to about 10 mL, preferably about 2 to about 5 mL. The composition is rubbed over the skin to distribute the composition for absorption onto the skin.
  • In another example, the present invention provides articles comprising an antibacterial or antimicrobial polymeric composition of the present invention posited on a surface of a medium. The medium may be any article in which it is desirable to render a surface or part of a surface antibacterial or antimicrobial, including for example, catheters, needles, sutures, stents, implantable medical devices, contact lenses, root canal fillers, wound dressings, bum dressings, tissue culture plates, fibers and paper. The antibacterial or antimicrobial polymeric composition may be posited on a surface by applying the polymeric composition which comprises water and optionally another solvent and allowing the water or other solvent to evaporate. For example, a sheet of paper may be coated by forming a polymeric composition in water and optionally another solvent which does not dissolve paper, applying the polymeric composition to the entire surface of the paper and allowing the water or other solvent to dry, thereby forming a polymer coating over the entire surface of the paper.
  • Alternatively, the hydrophilic first comonomer and second comonorner may be grafted to the surface of a medium by plasma grafting and then quaternized with an alkyl bromide to form the antimicrobial surface. For example, 4-vinyl pyridine and poly(ethylene glycol) methyl ether methacrylate may be grafted to the surface of paper via plasma grafting and then quarternized with bromohexane to form the antimicrobial surface. In another example, the surface or more specifically paper surface may be acylated by reacting it with 4-bromobutyrylchloride while immersed in an appropriate solvent. The polymeric composition, formed for example, from 4-vinyl-pyridine and poly(ethylene glycol) methyl ether methacrylate may then be quaternized by the surface alkyl bromide groups.
  • The antibacterial or antimicrobial polymeric composition may be incorporated into a natural or synthetic fiber. For example, the polymeric composition may be incorporated on or into fibers used for clothing or paper. Paper made from such fiber may be suitable as a food wrapping, part of a temporary wound dressing, as a disinfectant wipe, or for paper used in medical settings such as doctors' offices and hospitals including magazines.
  • The polymeric composition may be soluble or insoluble, depending on whether the desired product should be able to release the antibacterial or antimicrobial polymeric composition or retain the antibacterial or antimicrobial polymeric composition. In some aspects, the polymeric composition may be temporarily posited on the fibers for release onto a desired surface or into a desired environment at a later time. For example, a soluble polymeric composition may be used in a disinfectant wipe. The disinfectant wipe, which may be an alcohol based disinfectant wipe, releases the antibacterial or antimicrobial polymeric composition to another surface, imparting long-lasting antimicrobial properties to the applied surface.
  • In another example, the present invention provides methods for rendering a material or area bactericidal or antimicrobial. In a further example, the present invention provides a method for killing or significantly reducing the number of bacteria or microorganisms on a material or area treated with a bactericidal or antimicrobial composition of the present invention.
  • Accordingly, in one example, a bactericidal or antimicrobial composition of the present invention is applied to a medium or medical device in an amount sufficient to kill or significantly reducing the number of bacteria or microbes in or on the treated medium compared to an untreated medium. In a further example, a bactericidal or antimicrobial composition according to the present invention is applied to a medium or medical device in an amount sufficient to kill at least one bacterium or microbe or significantly reduce bacterial or microbial growth compared to an untreated medium.
  • The bacteria may be Gram-positive or Gram-negative. The bactericidal or antimicrobial composition may be is included in or coated onto a catheter, stent, implantable medical device, contact lens, root canal filler, or wound dressing. The treated medium may include natural or synthetic materials, implantable devices, or bodily surfaces. The treated medium may be contact with an aqueous environment, such as water or the inside of a patient or other vertebrate organism. Alternatively, the treated medium may be contact with air or air and/or air borne bacteria in an external environment or an enclosed bodily organ, such as lung.
  • Biocompatibility may be evaluated by any suitable methodology known in the art, including one or more viability/cytotoxicity assays known to those of ordinary skill in the art.
  • In a further example, the present invention provides a method for identifying a polymer having suitable bactericidal or antimicrobial activity. In this method, a hydrophilizing first comonomer may be polymerized to a second comonomer and a bactericidal or antimicrobial polymeric composition is formed. The bactericidal or antimicrobial polymeric composition may be applied to a medium to form a first treated medium and the medium may be separately treated with the second comonomer used in the first treated medium. The first treated medium and the second treated medium may be separately contacted with a plurality of bacteria or microbes. Whether the first treated medium is more bactericidal or antimicrobial than the second treated medium may be determined.
  • In a further example, a first polymeric composition and a second polymeric composition differing by molecular weight with regard to one or more corresponding comonomers may be separately applied to a medium and tested to identify a polymeric composition having improved bactericidal or antimicrobial activity.
  • Alternatively, a first polymeric composition and a second polymeric composition differing by molar ratio of their corresponding comonomers may be varied and may be separately applied to a medium and tested to identify a polymeric composition having improved bactericidal or antimicrobial activity.
  • In the above disclosed methods, a given polymeric composition may be rendered bactericidal or antimicrobial by quaternization after polymerizing the hydrophilizing first comonomer to the second comonomer. Accordingly, the quaternized polymeric composition would be deemed suitable for use in a bactericidal or antimicrobial composition if a medium containing or treated with the quaternized polymeric composition is more hydrophilic and/or bactericidal or antimicrobial than the same medium containing or treated with the quaternized second comonomer alone.
  • Bactericidal or antimicrobial activity may be evaluated using any suitable testing methodology used in the art, including, but not limited to, luminescence, optical density, or microscopic evaluation of bacterial or microbial growth or viability of coated and/or stained microscopic slides, plates or cultures.
  • The following examples illustrate features in accordance with the present invention, and are provided solely by way of illustration. They are not intended to limit the scope of the appended claims or their equivalents.
  • EXAMPLES
  • 1. Radical Polymerization and Quaternization. Copolymers possessing suitable bactericidal properties and a suitable hydrophilicityibiocompatibility profile were obtained using a quaternized polymeric composition synthesized from 4-vinylpyridine and a biocompatible, hydrophilic comonomer, such as hydroxyethylmethacrylate (HEMA) or poly(ethyleneglycol) methacrylate.
  • Copolymers were synthesized by radical copolymerization with AIBN as initiator. The reactants were stirred at 70° C. for 48 hours under flowing N2 to prevent oxidation. As the monomer contents were varied, the AIBN proportion was held constant to a massic ratio VP+PEGMA:AIBN equal to 22:1. To investigate the effects of hydrophilization, seven different compositions of VP with PEGMA300, PEGMA1100 and HEMA were synthesized, containing a molar percentage of VP of 10, 25, 50, 75, 90, 95 and 99.
  • Copolymers were quaternized with a 3-fold excess of hexyl bromide (HB) in a mixture of chloroform and methanol by reflux for 48 hr. They were precipitated in hexane, recovered and dried under vacuum. A schematic of the radical polymerization and quaternization process can be seen in FIG. 1,
  • Synthesis of P(VP-co-HEMA), P(VP-co-PEGMA300) and P(VP-co-PEGMA1100) was followed with FTIR and NMR. Spectroscopy showed that the synthesis was successful and that the quaternization went to near completion and that the resultant products were relatively pure after work-up.
  • VP, HEMA and PEGMA were purchased from Sigma Aldrich Co. (Milwaukee, USA). To avoid polymerization through heat or light, these monomers were inhibited with hydroquinone (HQ), 4-Methoxyphenol (MEHQ), and 2,6-di-tert-butyl-4-methylphenol (BHT) respectively. The HQ and MEHQ inhibitors were removed by means of trap to trap while BHT was purified from PEGMA by column chromatography on silica gel (70-270 mesh) stationary phase.
  • 2. Antimicrobial Hand Gel
  • An antimicrobial polymeric composition is prepared by dissolving the polymeric composition in water or a mixture of ethanol and water, such as 70% ethanol 30% water. The thickener is then added, and the resulting mixture is heated with stirring and kept below 70° C. until dissolution.
  • A P(VP-co-PEGMA300) hand gel was prepared by mixing 0.01 g of P(VP-co-HEMA) with 10 mL of water. Hydroxyethyl cellulose (0.013 a) was added, and the resulting mixture heated to 70° C., then cooled to room temperature.
  • 3. Contact Angle and Bactericidal Testing. To evaluate wettability, or hydrophilicity, contact angle tests were conducted by dip coating microscope slides in solutions with copolymer dissolved in chloroform and methanol. Contact angle measurements were obtained on a Ramé-Hart Advanced Goniometer.
  • Bactericidal tests were performed with a small quantity of the bacteria Escherichia coil O157:H7 in which the lux gene was added for luminescence, which provides a measure of metabolic growth or activity. A sample was taken from a culture and placed in contact with the coated slides, by means of a pipette. The intensity of the bioluminescence was recorded as a function of time for two hours with a photomultiplier tube. Reduced bioluminescence correlates with enhanced bactericidal activity.
  • 4. Bactericidal activity of PO/P-co-HEMA). The results of the bactericidal tests on quaternized copolymers of VP and HEMA are shown in FIG. 2. An initial increase of intensity is observed in the control, due to the fast growth of the bacteria, called blooming, After approximately 19 minutes, the intensity starts decreasing as the bacteria start to die. PVP-HB, known to kill bacteria, prevents blooming, as reflected by the fact that the intensity never increases by more than 1 percent. The intensity starts decreasing after only 7 minutes. Since this is much earlier than the control, the death of the bacteria CaO be attributed to the properties of the polymer. An uninterrupted blooming is observed for a slide coated with PHEMA, and the number of bacteria has quadrupled after two hours, following a lag-log behavior. This indicates that PHEMA by itself is not bactericidal.
  • P(VP-co-HEMA)-HB 95/5 and P(VP-co-HEMA)-HB 90/10 exhibited enhanced bactericidal activity compared to PVP-HB alone, The luminescence recorded for P(VP-co-HEMA)-HB 99/1, is similar to, but slightly less than that observed for PVP-HB alone. Accordingly, this copolymer, having one molar percent HEMA, displays properties similar to PVP-HB alone. However, a slide coated with P(VP-co-HEMA)-HB 99/1 kills bacteria faster than one coated with PVP-HB.
  • The wettability of dry, vitreous HEMA-based materials was studied by contact angle measurements. The results for both advancing and receding angles are given in FIG. 3. Contact angle measurements showed an increase in hydrophilicity provoked by the copolymerization, The surface energy was found to be minimal for P(VP-co-HEMA) at 90/10 and slightly higher for P(VP-co-HEMA)-HB 99/1. This corresponds to the bactericidal behavior of the polymers and suggests that the wettability plays a significant role in the polymer's effectiveness. Being a hydrogel monomer, HEMA hydrophilizes the copolymer.
  • Although not wishing to be bound by theory, it is believed that coupling hydrophilization to bactericidal activity in the polymer facilitates enhances bacterial killing in part because of the water-loving nature of bacteria: a hydrophilic growth medium is better able to support uptake and killing by a hydrophilized bactericidal polymer compared to an unhydrophilized bactericidal polymer. It is further believed that the hydrophilized bactericidal polymers of the present invention to unexpectedly possess enhanced biocompatility characteristics, enhanced stabilization of blood cells compared to saline and decreased absorption to proteins and lipids.
  • In P(VP-co-HEMA)-HB 90/10, the wettability effect is particularly evident. This polymer exhibits a more optimal bactericidal activity, reflected in the fact that all bacteria were killed in 30 minutes. This further illustrates that that a slide coated with P(VP-co-HEMA)-HB 90/10 copolymer is significantly more bactericidal than pure PVP-HB.
  • 5. Bactericidal activity of P(VP-co-PEGMA). The bacterial growth behavior for copolymers with PEGMA1100 can be seen in FIG. 4. Comonomer ratios of 90/10, 25/75, and 10/90 exhibited enhanced bactericidal activity compared to PVP-HB alone. Extremely high bactericidal activity was seen with ratios of 99/1, presumably due to the large fraction of VP and improved wettability from PEGMA1100. Copolymers with ratios ranging from 95/5 to 50/50 displayed bacterial results similar to PVP-HB.
  • P(VP-co-PEGMA1100)-HB 25/75 and 10/90 displayed a surprisingly high antibacterial activity. Although counterintuitive, this fact can have several explanations. The molecular weight of P(VP-co-PEGMA1100)-HB 10/90 is much higher than other copolymer formulations of this system. This could increase bactericidal activity, because the copolymer possesses more alkyl tails to traverse the bacterial membranes. The enhanced water wettability of the polymer may enable the polymer to better dissolve in and/or surround the bacteria in an aqueous medium, so as to facilitate more efficient bacterial killing.
  • PPEGMA300 (graph not shown) alone does not kill bacteria and actually improves growth due to its biocompatibility and hydrophilicity. The improved biocompatibility and hydrophilicity is carried over into the P(VP-co-PEGMA300) copolymers with ratios from 0/100 to 50/50 thereby improving bacterial growth. However, for ratios greater 50/50, bactericidal activity was observed. The optimum balance between spreading and VP content was found to be 75/25, in which half the bacteria were killed in the first 15 minutes. Overall, the bactericidal behavior of the PEGMA300 based polymers were reduced compared to PEGMA1100 based polymers.
  • PEGMA1100 has a significantly larger PEG size than PEGMA300. A smaller fraction of PEGMA1100 is thus necessary to hydrophilize P(VP-co-PEGMA1100). However, even for some similarly hydrophilized polymers, the PEGMA1100 materials exhibit superior bactericidal activity, possibly due to the enhanced protein resistance imparted by longer PEG chains in the polymers.
  • The enhanced bactericidal activity exhibited by the HEMA and PEGMA copolymers appears to result from enhanced wettability in aqueous solutions, allowing the polymer to better surround and/or gain access to the bacteria, so as to enhance bacterial killing.
  • 6. Cytotoxity of P(VP-co-PEGMA). A viabilitylcytotoxicity assay may be used to evaluate biocompatibility of the bactericidal polymers for mammalian cells. In particular, FIG. 5 shows that an exemplary bactericidal PEGMA 1100 copolymer is non-toxic to mammalian cells. Corneal epithelial cells were seeded onto polystyrene culture plates in phosphobuffered saline solution (PBS; pH 7.2) at a density of 3,500 cells/cm2 for 24 hrs at 37° C. The cells were co-incubated for 4 hrs. with quaternized P(VP-co-PEGMA 1100) copolymer or PPEGMA control polymer in PBS at a concentration of 2.5 mg/ml, along with a PBS negative control media.
  • Live cells were distinguished from dead cells using a fluorescence-based LIVE/DEAD viability/cytotoxicity assay system (Molecular Probes, Invitrogen Detection Technologies). The assay system includes two probes, calcein AM, a fluorogenic esterase substrate producing a green fluorescent product in live cells having intracellular esterase activity, and ethidium homodimer-1, a high-affinity, red fluorescent dye only able to pass through and stain the compromised membranes of dead cells. FIG. 5 plots the fraction of dead epithelial cells as a function of added bactericidal polymer or polymer control. As shown in FIG. 5, treatment of epithelial cells with the bactericidal P(VP-co-PEGMA) polymer did not exhibit a statistically significant level of epithelial cell killing over that of the PEGMA polymer or PBS negative controls.
  • It is to be understood that the above-described polymers and methods for their use are merely representative embodiments illustrating the principles of this invention and that other variations in the polymers or methods, may be devised by those skilled in the art without departing from the spirit and scope of his invention. The foregoing detailed description and accompanying drawings have been provided solely by way of explanation and illustration, and are not intended to lirnit the scope of the appended claims. Many variations in the presently preferred embodiments illustrated herein will be apparent to one of ordinary skill in the art, and remain within the scope of the appended daims and theft equivalents.

Claims (26)

What is claimed is:
1. A composition comprising a copolymer formed from a hydrophilic first comonomer having an acrylate moiety and a second pyridinium-type comonomer containing a nitrogen atom and a vinyl moiety, wherein the first comonomer and the second comonomer are chemically bonded within the copolymer through the acrylate moiety of the first comonomer and the vinyl moiety of the second comonomer, wherein said nitrogen atom is quaternized with an alkyl moiety such that said copolymer is polycationic, and wherein the amounts of the first comonomer and the second comonomer provide said copolymer with
a. improved bactericidal activity as compared to the first comonomer; and
b. improved bactericidal activity as compared to the second comonomer.
2. The composition of claim 1, wherein the hydrophilic first comonomer comprises hydroxyethylmethacrylate.
3. The composition of claim 1, wherein the hydrophilic first comonomer comprises poly(ethylene glycol) methacrylate.
4. The composition of claim 1, wherein the second comonomer comprises 4-vinylpyridine.
5. The composition of claim 1 wherein said nitrogen is quaternized with an alkyl moiety.
6. The composition of claim 1 further comprising a halide anion associated with a cation of the quaternized nitrogen of the polycationic copolymer.
7. The composition of claim 6 wherein the anion comprises a bromide anion.
8. The composition of claim 5 wherein the alkyl moiety comprises a hexyl moiety.
9. The composition of claim 8 further comprising a halide anion associated with a cation of the quaternized nitrogen of the polycationic copolymer.
10. The composition of claim 9 wherein the halide anion comprises a bromide anion.
11. The composition of claim 1, wherein the hydrophilic first comonomer comprises at least one selected from poly(ethylene glycol) methacrylate and hydroxyethylmethacrylate and the second comonomer comprises 4-vinylpyridine.
12. The composition of claim 11 wherein the first comonomer comprises poly(ethylene glycol) methacrylate having a molecular weight of at least about 300 Daltons.
13. The composition of claim 12 wherein the molecular weight of said poly(ethylene glycol) methacrylate is less than about 2000 Daltons.
14. The composition of claim 12 wherein said copolymer contains at least about 1 mol percent of said poly(ethylene glycol) methacrylate.
15. The composition of claim 11 wherein the first comonomer comprises hydroxyethylmethacrylate.
16. The composition of claim 11 wherein said nitrogen is quaternized with an alkyl moiety.
17. The composition of claim 11 further comprising a halide anion associated with a cation of the quaternized nitrogen of the polycationic copolymer.
18. The composition of claim 17 wherein the anion comprises a bromide anion.
19. The composition of claim 16 wherein the alkyl moiety comprises a hexyl moiety.
20. The composition of claim 19 further comprising a halide anion associated with a cation of the quaternized nitrogen of the polycationic copolymer.
21. The composition of claim 20 wherein the halide anion comprises a bromide anion.
22. The composition of claim 12 wherein the alkyl moiety comprises a hexyl moiety.
23. The composition of claim 12 further comprising a bromide anion associated with a cation of the quaternized nitrogen of the polycationic copolymer.
24. The composition of claim 22 further comprising a bromide anion associated with a cation of the quaternized nitrogen of the polycationic copolymer.
25. The composition of claim 1 wherein the copolymer is a random copolymer.
26. The composition of claim 1 wherein the copolymer is a block copolymer.
US14/087,188 2005-08-24 2013-11-22 Hydrophilized antimicrobial polymers Abandoned US20140080977A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/087,188 US20140080977A1 (en) 2005-08-24 2013-11-22 Hydrophilized antimicrobial polymers

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US71123405P 2005-08-24 2005-08-24
US11/509,915 US20070048249A1 (en) 2005-08-24 2006-08-24 Hydrophilized bactericidal polymers
US12/549,004 US8343473B2 (en) 2005-08-24 2009-08-27 Hydrophilized antimicrobial polymers
US13/682,159 US20130079481A1 (en) 2005-08-24 2012-11-20 Hydrophilized antimicrobial polymers
US13/748,290 US20130136783A1 (en) 2005-08-24 2013-01-23 Hydrophilized antimicrobial polymers
US14/087,188 US20140080977A1 (en) 2005-08-24 2013-11-22 Hydrophilized antimicrobial polymers

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/748,290 Continuation US20130136783A1 (en) 2005-08-24 2013-01-23 Hydrophilized antimicrobial polymers

Publications (1)

Publication Number Publication Date
US20140080977A1 true US20140080977A1 (en) 2014-03-20

Family

ID=41415012

Family Applications (4)

Application Number Title Priority Date Filing Date
US12/549,004 Active - Reinstated 2027-11-22 US8343473B2 (en) 2005-08-24 2009-08-27 Hydrophilized antimicrobial polymers
US13/682,159 Abandoned US20130079481A1 (en) 2005-08-24 2012-11-20 Hydrophilized antimicrobial polymers
US13/748,290 Abandoned US20130136783A1 (en) 2005-08-24 2013-01-23 Hydrophilized antimicrobial polymers
US14/087,188 Abandoned US20140080977A1 (en) 2005-08-24 2013-11-22 Hydrophilized antimicrobial polymers

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US12/549,004 Active - Reinstated 2027-11-22 US8343473B2 (en) 2005-08-24 2009-08-27 Hydrophilized antimicrobial polymers
US13/682,159 Abandoned US20130079481A1 (en) 2005-08-24 2012-11-20 Hydrophilized antimicrobial polymers
US13/748,290 Abandoned US20130136783A1 (en) 2005-08-24 2013-01-23 Hydrophilized antimicrobial polymers

Country Status (1)

Country Link
US (4) US8343473B2 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015153119A1 (en) * 2014-03-31 2015-10-08 Kimberly-Clark Worldwide, Inc. Self-regenerating antimicrobial composition and method of use
WO2016086012A1 (en) * 2014-11-26 2016-06-02 Microban Products Company Surface disinfectant with residual biocidal property
WO2017091251A1 (en) * 2015-11-23 2017-06-01 Microban Products Company Surface disinfectant with residual biocidal property
WO2017091250A1 (en) * 2015-11-23 2017-06-01 Microban Products Company Surface disinfectant with residual biocidal property
US9982121B2 (en) 2016-07-11 2018-05-29 Samsung Electronics Co., Ltd. Pyridinium modified composite, and article including same
WO2018232417A1 (en) * 2017-06-16 2018-12-20 Poly Group LLC Polymeric antimicrobial surfactant
US10174144B2 (en) 2013-09-27 2019-01-08 Construction Research & Technology, Gmbh Cationic copolymers
US10842147B2 (en) 2014-11-26 2020-11-24 Microban Products Company Surface disinfectant with residual biocidal property
US10925281B2 (en) 2014-11-26 2021-02-23 Microban Products Company Surface disinfectant with residual biocidal property
US11033023B2 (en) 2014-11-26 2021-06-15 Microban Products Company Surface disinfectant with residual biocidal property
US11134684B2 (en) 2005-08-24 2021-10-05 Purdue Research Foundation Method of using hydrophilized bactericidal polymers
US11421084B2 (en) 2017-05-27 2022-08-23 Poly Group LLC Dispersible antimicrobial complex and coatings therefrom
US11503824B2 (en) 2016-05-23 2022-11-22 Microban Products Company Touch screen cleaning and protectant composition

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206511B2 (en) * 2009-10-06 2012-06-26 Ecolab Usa Inc. Daily cleaner with slip-resistant and gloss-enhancing properties
US9920281B2 (en) 2009-11-12 2018-03-20 Ecolab Usa Inc. Soil resistant surface treatment
CN103328623B (en) 2010-12-13 2015-04-01 艺康美国股份有限公司 Soil resistant floor cleaner
CN102690481B (en) * 2012-05-11 2015-11-25 北京化工大学 A kind of Composite antimicrobial of nanometer silver bromide polymer and preparation method thereof
WO2019152023A1 (en) * 2018-01-31 2019-08-08 KeraMed, Inc. Antimicrobial polymer for use in ophthalmic implants
CN112239513B (en) * 2019-07-18 2022-09-20 南京理工大学 Intrinsic self-repairing bactericidal polymer and preparation method thereof
US11988471B2 (en) 2021-03-27 2024-05-21 Massachusetts Institute Of Technology Devices and methods for fabrication of components of a multiscale porous high-temperature heat exchanger
CN116813825B (en) * 2023-06-29 2024-06-04 征鸿诺瓦医疗科技(深圳)有限公司 Preparation method of crosslinkable cationic polymer antibacterial coating

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414353A (en) * 1977-06-03 1983-11-08 Hercules Incorporated Organic pigments
IT1140999B (en) 1980-06-18 1986-10-10 Italfarmaco Spa MODIFIED GLYCOSAMINOGLICANS EQUIPPED WITH ANTI-LIPEMIC ACTIVITY AND WITHOUT ANTI-COAGULANT ACTIVITY
US4482680A (en) 1981-09-15 1984-11-13 Dynapol Quaternary ammonium group-containing polymers having antimicrobial activity
GB8829835D0 (en) * 1988-12-21 1989-02-15 Smith Kline French Lab Compounds
US4931522A (en) 1989-07-11 1990-06-05 Robert Catena Copolymers of polyalkylene glycol acrylate and a salt of a quarternized acrylate
JP3162696B2 (en) 1989-09-06 2001-05-08 ライオン株式会社 Water-soluble, salt-sensitive polymer
TW228529B (en) 1992-12-23 1994-08-21 Ciba Geigy
US5509899A (en) 1994-09-22 1996-04-23 Boston Scientific Corp. Medical device with lubricious coating
US6221425B1 (en) 1998-01-30 2001-04-24 Advanced Cardiovascular Systems, Inc. Lubricious hydrophilic coating for an intracorporeal medical device
AU4980199A (en) 1998-07-08 2000-02-01 Sunsoft Corporation Interpenetrating polymer network hydrophilic hydrogels for contact lens
US6358557B1 (en) 1999-09-10 2002-03-19 Sts Biopolymers, Inc. Graft polymerization of substrate surfaces
US6559116B1 (en) 1999-09-27 2003-05-06 The Procter & Gamble Company Antimicrobial compositions for hard surfaces
US6815502B1 (en) 2000-05-04 2004-11-09 Kimberly-Clark Worldwide, Inc. Ion-sensitive, water-dispersable polymers, a method of making same and items using same
US6537663B1 (en) 2000-05-04 2003-03-25 Kimberly-Clark Worldwide, Inc. Ion-sensitive hard water dispersible polymers and applications therefor
CA2415871A1 (en) 2000-08-24 2002-02-28 Novartis Ag Process for surface modifying substrates and modified substrates resulting therefrom
US6852353B2 (en) 2000-08-24 2005-02-08 Novartis Ag Process for surface modifying substrates and modified substrates resulting therefrom
KR100904284B1 (en) 2001-03-08 2009-06-25 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Facially amphiphilic polymers as anti-infective agents
US7151139B2 (en) 2001-04-23 2006-12-19 Massachusetts Institute Of Technology Antimicrobial polymeric surfaces
FR2824832B1 (en) 2001-05-16 2005-05-27 Oreal WATER-SOLUBLE WATER-SOLUBLE SKELETOLYMERIC POLYMERS WITH LCST LATERAL UNITS, PROCESS FOR THEIR PREPARATION, AQUEOUS COMPOSITIONS CONTAINING SAME, AND USE THEREOF IN THE COSMETIC FIELD
US6815074B2 (en) 2001-05-30 2004-11-09 Novartis Ag Polymeric materials for making contact lenses
FR2833186B1 (en) 2001-12-12 2004-01-23 Rhodia Chimie Sa USE OF CATIONIC BLOCK COPOLYMERS AS AID FOR DEPOSITION OF SINGLE OR MULTIPLE EMULSIONS
US20050008839A1 (en) 2002-01-30 2005-01-13 Cramer Ronald Dean Method for hydrophilizing materials using hydrophilic polymeric materials with discrete charges
CN1200030C (en) 2002-02-05 2005-05-04 复旦大学 One-step process for preparing nano micelles of polymer with stable core-shell structure and high concentration
US6846892B2 (en) 2002-03-11 2005-01-25 Johnson & Johnson Vision Care, Inc. Low polydispersity poly-HEMA compositions
US7618617B2 (en) * 2002-05-31 2009-11-17 L'oreal Aqueous hair treatment compositions, thickened with an amphiphilic linear block copolymer
US8172395B2 (en) 2002-12-03 2012-05-08 Novartis Ag Medical devices having antimicrobial coatings thereon
US20050008676A1 (en) 2002-12-19 2005-01-13 Yongxing Qiu Medical devices having antimicrobial coatings thereon
US8425926B2 (en) 2003-07-16 2013-04-23 Yongxing Qiu Antimicrobial medical devices
KR20060041247A (en) 2003-07-18 2006-05-11 시바 스페셜티 케미칼스 홀딩 인크. Ink jet recording medium
US20050101740A1 (en) * 2003-09-01 2005-05-12 Nathalie Mougin Block ethylenic copolymers comprising a vinyllactam block, cosmetic compositions containing them and cosmetic use of these copolymers
US7112559B1 (en) 2005-03-14 2006-09-26 Ecolab Inc. Thickened quaternary ammonium compound sanitizer

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11459415B2 (en) 2005-08-24 2022-10-04 Purdue Research Foundation Method of using hydrophilized bactericidal polymers
US11134684B2 (en) 2005-08-24 2021-10-05 Purdue Research Foundation Method of using hydrophilized bactericidal polymers
US10174144B2 (en) 2013-09-27 2019-01-08 Construction Research & Technology, Gmbh Cationic copolymers
GB2540688A (en) * 2014-03-31 2017-01-25 Kimberly Clark Co Self-regenerating antimicrobial composition and method of use
GB2540688B (en) * 2014-03-31 2021-04-21 Kimberly Clark Co Self-regenerating antimicrobial composition and method of use
WO2015153119A1 (en) * 2014-03-31 2015-10-08 Kimberly-Clark Worldwide, Inc. Self-regenerating antimicrobial composition and method of use
US10104894B2 (en) 2014-03-31 2018-10-23 Kimberly-Clark Worldwide, Inc. Self-regenerating antimicrobial composition and method of use
US10925281B2 (en) 2014-11-26 2021-02-23 Microban Products Company Surface disinfectant with residual biocidal property
US11134674B2 (en) 2014-11-26 2021-10-05 Microban Products Company Surface disinfectant with residual biocidal property
RU2733134C2 (en) * 2014-11-26 2020-09-29 Майкробан Продактс Компани Disinfectant for surfaces, having residual biocidal properties
US10834922B2 (en) 2014-11-26 2020-11-17 Microban Products Company Surface disinfectant with residual biocidal property
US10842147B2 (en) 2014-11-26 2020-11-24 Microban Products Company Surface disinfectant with residual biocidal property
WO2016086012A1 (en) * 2014-11-26 2016-06-02 Microban Products Company Surface disinfectant with residual biocidal property
US11134678B2 (en) 2014-11-26 2021-10-05 Microban Products Company Surface disinfectant with residual biocidal property
US11026418B2 (en) 2014-11-26 2021-06-08 Microban Products Company Surface disinfectant with residual biocidal property
US11033023B2 (en) 2014-11-26 2021-06-15 Microban Products Company Surface disinfectant with residual biocidal property
WO2017091251A1 (en) * 2015-11-23 2017-06-01 Microban Products Company Surface disinfectant with residual biocidal property
WO2017091250A1 (en) * 2015-11-23 2017-06-01 Microban Products Company Surface disinfectant with residual biocidal property
US11503824B2 (en) 2016-05-23 2022-11-22 Microban Products Company Touch screen cleaning and protectant composition
US9982121B2 (en) 2016-07-11 2018-05-29 Samsung Electronics Co., Ltd. Pyridinium modified composite, and article including same
US11421084B2 (en) 2017-05-27 2022-08-23 Poly Group LLC Dispersible antimicrobial complex and coatings therefrom
US11760844B2 (en) 2017-05-27 2023-09-19 Poly Group LLC Dispersible antimicrobial complex and coatings therefrom
WO2018232417A1 (en) * 2017-06-16 2018-12-20 Poly Group LLC Polymeric antimicrobial surfactant
US11680116B2 (en) 2017-06-16 2023-06-20 Poly Group LLC Polymeric antimicrobial surfactant

Also Published As

Publication number Publication date
US20130079481A1 (en) 2013-03-28
US20130136783A1 (en) 2013-05-30
US8343473B2 (en) 2013-01-01
US20090311302A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
US11459415B2 (en) Method of using hydrophilized bactericidal polymers
US8343473B2 (en) Hydrophilized antimicrobial polymers
L Zubris et al. Polymeric quaternary ammonium compounds: versatile antimicrobial materials
JP6400666B2 (en) Cross-linked zwitterionic hydrogel
US9750847B2 (en) Chitosan hydrogel derivatives as a coating agent with broad spectrum of antimicrobial activities
US10676501B2 (en) Hydrogel materials incorporating eluting ceragenin compound
US8512795B2 (en) Hydrophilic coating comprising a polyelectrolyte
CN108603136B (en) Coating solution, coating formed therefrom, and coated medical device
EP3380536B1 (en) A polymeric composition
EP1020495B1 (en) Ion complex, coating material, and coating method
CN101478976A (en) Polymers with antimicrobial activity containing quaternary ammonium groups
CN107286355B (en) Cation-zwitterion copolymer and polycaprolactone blended membrane and preparation method and application thereof
US20200085045A1 (en) Antimicrobial polymers and antimicrobial hydrogels
Arora et al. Polymer based antimicrobial coatings as potential biomaterial: A review
CN104857550B (en) Polylysine-p-hydroxyphenylpropionic acid antibacterial hydrogel dressing and preparation method thereof
Lane et al. Sustained tobramycin release from polyphosphate double network hydrogels
Gupta et al. N-vinylpyrrolidone antimicrobial polymers: current trends and emerging perspectives
Biswas et al. Structurally Heterogeneous Amphiphilic Conetworks of Poly (vinyl imidazole) Derivatives with Potent Antimicrobial Properties and Cytocompatibility
CN114702624A (en) Polysaccharide polymer based antibacterial material and preparation method thereof
CN117563055A (en) Super-lubrication anti-biofilm hydrogel crosslinked coating, and preparation method and application thereof
Mutar Chloramphenicol controlled release from Poly (acrylic acid-co-methyl methacrylate) hydrogels
EP3973934A1 (en) Polycationic polymer, composition comprising the polycationic polymer, and product, comprising an active surface, provided with the polycationic polymer
CN118215488A (en) Phosphate and arginine containing compositions and delivery of such compositions for virulence inhibition
JPH05269153A (en) Dental floss
JP2004137154A (en) Microbicidal material

Legal Events

Date Code Title Description
AS Assignment

Owner name: PURDUE RESEARCH FOUNDATION, INDIANA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YOUNGBLOOD, JEFFREY P.;SELLENET, PHILIPPE H.;STRATTON, THOMAS R.;SIGNING DATES FROM 20121206 TO 20130122;REEL/FRAME:031657/0316

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION